Answers are grounded in this paper and cite their sources.
Bladder cancer is among the most recurrence-prone malignancies, and its management remains anchored to invasive cystoscopy and cytology, which have limited sensitivity. Urine, which is in direct contact with the tumor, carries a rich molecular cargo, including urinary tumor-derived DNA (utDNA), the tumor-derived fraction of urinary cell-free DNA, alongside methylation marks, extracellular vesicle (EV) cargo, and exfoliated cells. These components can now be interrogated through multi-omics profiling and interpreted using artificial intelligence (AI). In this Mini Review, we integrate these layers into a single translational framework: microfluidic “urine-on-chip” technologies convert a drop of urine into standardized, analysis-ready multi-omic data, while machine learning and deep learning models—increasingly governed by STARD-AI/TRIPOD + AI reporting standards—transform these data into diagnostic, prognostic, and treatment-response predictions. We highlight clinically mature anchors, including the utMeMA methylation assay (90.0%/83.1%), the Uromonitor mutation test (TERT/FGFR3/KRAS; 80.2%/96.9%, meta-analysis), chip-based cytometry for detecting high-grade disease, and an externally validated autonomous urine cytology system. These figures are assay-specific and should not be interpreted as platform-wide benchmarks. Finally, we define the priorities—pre-analytical standardization, external validation, and cost-effectiveness—that will advance urinary multi-omic AI from its current performance level into routine practice along a “detect–decide–treat–monitor” digital management pathway.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: